On August 7, 2023 XNK Therapeutics reported that it will participate at the SITC (Free SITC Whitepaper) meeting in San Diego in November and present the latest research from the company’s leading preclinical projects in bladder cancer and acute myeloid leukemia (AML) (Press release, XNK Therapeutics, AUG 7, 2023, View Source [SID1234633893]). Two abstracts have been accepted for presentation at the meeting:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Harnessing the potential of autologous NK cells for immunotherapy of patients with advanced bladder cancer
Feeder-Free Expansion of Autologous Cytotoxic NK Cells for Acute Myeloid Leukemia Treatment
The data have been generated in collaboration with XNK’s external partners, Anders Ullén and Fernanda Costa Svedman at the Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden, for the bladder cancer abstract, and Abhishek Maiti and Naval Daver at The University of Texas MD Anderson Cancer Center in Houston, Texas, USA, for the AML abstract.

The yearly SITC (Free SITC Whitepaper) meeting is a multidisciplinary educational and interactive environment focused on improving outcomes for cancer patients by incorporating strategies based on basic and applied cancer immunotherapy. It consists of cutting-edge research presentations by experts in the field.

"We look forward to presenting at this prestigious conference, which both sheds more light on our exciting pipeline and gives us the opportunity to discuss our data with other experts in the field," said Anna-Karin Maltais, CSO of XNK Therapeutics.